Summary
International Defense Ministry Awards BIO-key over $600K in Follow-On Orders for Secure Biometric Access to Critical Information
International Defense Ministry Awards BIO-key (Nasdaq: BKYI) over $600K in Follow-On Orders for Secure Biometric Access to Critical Information #Biometrics
FibroBiologics to Present at the BIO International Convention 2025
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis.
Hoth Therapeutics to Attend 2025 BIO International Convention
NEW YORK , June 16, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, pioneering breakthrough therapies to improve the lives of patients, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the BIO International Convention, in Boston, MA, June 16-19,2025. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.
BIOME AUST FPO Dividends
BIOME AUST FPO Earnings
| 30 Jul 2025 (In 3 weeks) Date | | 1.76 Cons. EPS | - EPS |
| 5 May 2025 Date | | 1.78 Cons. EPS | 2.54 EPS |
| 13 Feb 2025 Date | | 2.88 Cons. EPS | 2.9 EPS |
| 30 Oct 2024 Date | | 1.16 Cons. EPS | 2.01 EPS |
| 24 Oct 2024 Date | | 2.51 Cons. EPS | - EPS |
| 30 Jul 2025 (In 3 weeks) Date | | 1.76 Cons. EPS | - EPS |
| 5 May 2025 Date | | 1.78 Cons. EPS | 2.54 EPS |
| 13 Feb 2025 Date | | 2.88 Cons. EPS | 2.9 EPS |
| 30 Oct 2024 Date | | 1.16 Cons. EPS | 2.01 EPS |
| 24 Oct 2024 Date | | 2.51 Cons. EPS | - EPS |
BIOME AUST FPO (BIO) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has BIOME AUST FPO ever had a stock split?
BIOME AUST FPO Profile
| Medical - Devices Industry | Healthcare Sector | Norman D. Schwartz CEO | CXA Exchange | US0905722072 ISIN |
| US Country | 7,700 Employees | - Last Dividend | 8 Mar 2002 Last Split | - IPO Date |
Overview
Bio-Rad Laboratories, Inc., founded in 1952 and based in Hercules, California, is a prominent provider of life science research and clinical diagnostic products globally, serving customers in the United States, Europe, Asia, Canada, and Latin America. The company operates in two key segments: Life Science and Clinical Diagnostics. With a strong commitment to innovation and quality, Bio-Rad develops, manufactures, and distributes a wide range of instruments, systems, reagents, and consumables designed to advance scientific understanding and improve healthcare outcomes. The firm distributes its offerings through a direct sales force, alongside a network of distributors, agents, brokers, and resellers, ensuring broad and effective market reach.
Products and Services
Bio-Rad Laboratories, Inc. offers a vast array of products and services tailored to meet the needs of various markets, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety, as well as clinical diagnostics.
- Life Science Research Products:
These include instruments, systems, reagents, and consumables for the separation, purification, characterization, and quantitation of biological materials like cells, proteins, and nucleic acids. These products support critical research areas in proteomics and genomics, empowering scientists to make groundbreaking discoveries in biology and medicine.
- Clinical Diagnostics Products:
Bio-Rad offers an extensive range of test systems, informatics systems, test kits, and specialized quality controls. These are designed for application in various settings including hospitals, diagnostic reference labs, transfusion services, and physician office laboratories. The clinical diagnostics segment focuses on providing accurate and reliable tools for the diagnoses of diseases and the monitoring of treatment efficacy.
- Biopharmaceutical Production Supplies:
This range supports the production of biopharmaceuticals with a focus on the purification and analysis of biological materials. Bio-Rad's products in this category are essential for ensuring the safety and efficacy of biopharmaceuticals, including vaccines, antibodies, and therapeutic proteins.
- Food Safety Testing Products:
Bio-Rad also provides robust solutions for testing the safety of food products. These include reagents, instruments, and systems that help detect potentially harmful contaminants in food, ensuring compliance with international food safety standards and protecting public health.
Contact Information
